Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Adagene's Pre-Tax Income for the
six
months ended in Dec. 2025 was €-3.78 Mil. Adagene's Revenue for the
six
months ended in Dec. 2025 was €6.55 Mil. Therefore, Adagene's pretax margin for the quarter that ended in Dec. 2025 was -57.75%.
The historical rank and industry rank for Adagene's Pretax Margin % or its related term are showing as below:
FRA:978'
s Pretax Margin % Range Over the Past 10 Years
Min: -32467.96 Med: -932.97 Max: -95.27
Current: -233.44
FRA:978's Pretax Margin % is ranked worse than 61.97% of 944
companies
in the Biotechnology industry
Industry Median: -90.5
vs FRA:978: -233.44
Adagene (FRA:978) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Adagene Pretax Margin % Related Terms
Adagene Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Adagene's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:978 vs RNAC, LYEL, ALXO: Pretax Margin % Comparison
For the Biotechnology subindustry, Adagene's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adagene Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adagene's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Adagene's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adagene (FRA:978) has a Pretax Margin % of -57.75% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Adagene and its competitors. According to the industry distribution chart, Adagene ranks #585 out of 944 companies in the Biotechnology industry, placing it in the top 62%.
Is Adagene's Pretax Margin % too high?
Adagene's current Pretax Margin % is -57.75%. Based on the distribution chart, Adagene ranks #585 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's Pretax Margin % compare to RNAC and LYEL?
According to the Biotechnology industry distribution chart, Adagene ranks #585 out of 944 companies for Pretax Margin %. This places Adagene in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Adagene and its competitors. Adagene's current Pretax Margin % is -57.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current Pretax Margin % of -57.75%. The stock's GF Value™ is €11.74, compared to a current price of €3.48 — trading 70.4% below its estimated fair value. The current Pretax Margin % is -57.75%. Adagene's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Adagene (FRA:978), the current Pretax Margin % is -57.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adagene (FRA:978) Overvalued in 2026?
Based on GuruFocus' analysis, Adagene stock appears to be undervalued.
The current stock price of €3.48 is trading 70.4% below its estimated GF Value™ of €11.74.
Key valuation signals for FRA:978:
Pretax Margin %: -57.75%
GF Value™: €11.74 vs. price of €3.48 (70.4% below fair value)
No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score
Get the complete analysis for FRA:978
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:978 has been successfully added to your 
